INTRODUCTION
Candida species are the leading cause of invasive fungal infections in hospitalized patients and are the fourth most common cause of bloodstream infections. [1] The reported crude mortality rates due to candidemia range from 30% to 81%. [2] Risk factors include exposure to broad-spectrum antibacterial agents, diabetes, increased complexity of surgical procedures, prolonged use of central venous catheters, renal failure, dialysis, total parenteral nutrition, underlying malignancy, corticosteroids, and cytotoxic chemotherapy.
patients have led to a notable shift from infections with C. albicans to infections with nonalbicans Candida species. [7] MATERIALS AND METHODS A retrospective study was conducted in a Tertiary Care Center in North India from January 1, 2014 to March 31, 2015. Candidemia was defined as the isolation of Candida species from one or more blood culture samples of a patient. [2] Blood culture was performed using the semi-automated BACTEC system. Candida species isolated from patient's blood culture were identified up to the species level, using standard microbiological techniques, which included germ tube test, corn meal agar morphology, CHROMagar, sugar fermentation test, and sugar assimilation test [ Figure 1 ]. [8] Antifungal drug susceptibility was done by disk diffusion method according to the Clinical and Laboratory Standards Institute guidelines.
[9] The disks tested were clotrimazole (10 mcg), fluconazole (10 mcg), ketoconazole (10 mcg), itraconazole (10 mcg), and amphotericin B (100 units).
RESULTS
During the 15 months of the study, a total of 10893 blood cultures samples were processed of which 1440 (13.2%) were detected positive. Among the positive samples Candida species were isolated from 105 (7.3%) cases. Of these, 15 (14.3%) were C. albicans and 90 (85.7%) were nonalbicans Candida. Nonalbicans Candida included C. tropicalis −53 (50.5%), C. glabrata −20 (19.0%), C. parapsilosis −15 (14.3%), and one isolate each of Candida guillermondi and C. krusei [ Figure 2 ].
The majority of the C. albicans were resistant to commonly used antifungal drugs such as fluconazole (47%), itraconazole (60%), clotrimazole (47%), and ketoconazole (33%). Among the nonalbicans Candida spp., C. tropicalis showed 49% resistance to fluconazole, 42% resistance to ketoconazole, 60% resistance to clotrimazole, and 64% resistance to itraconazole. C. glabrata showed 55% resistance to clotrimazole, 45% resistance to fluconazole, 50% resistance to ketoconazole, and 65% to itraconazole. C. parapsilosis showed 60% resistance to clotrimazole, 27% to fluconazole and ketoconazole and 87% to itraconazole. C. krusei and C. guillermondi were resistant to fluconazole, ketoconazole, itraconazole and clotrimazole. All the isolates were uniformly sensitive to amphotericin B [ Figure 3 ].
Chi-square test was applied to compare the sensitivity of various azoles among C. albicans and nonalbicans Candida. The P value was found to be P > 0.5 which was suggestive that there was no significant difference in the susceptibility pattern between C. albicans and other species of Candida.
DISCUSSION
Candidemia is an emerging problem in healthcare settings. Recent studies have shown an increase in the incidence of candidemia due to nonalbicans Candida species with the isolation rate ranging from 50% to 96% from tertiary care centers in India. C. tropicalis and C. parapsilosis are an emerging cause of candidemia in India. [2] In our study, C. tropicalis caused 50.5% cases of candidemia. Previous studies by Chakrabarti et al, [10] Singh et al. [11] and Chander et al. [1] are in agreement with our study, and it appears that C. tropicalis is the predominant species causing candidemia in North India. Studies done by Adhikary et al. [12] and Giri et al. [13] in South India also showed a predominance of C. tropicalis that is consistent with our study.
However, studies done by Al-Rawahi and Roscoe [3] in Canada and Oliveira et al. [14] in Brazil showed predominance of C. albicans although the incidence of nonalbicans Candida species was on the rise. Recent study done in Shangai by Yang et al. [4] showed a predominance of nonalbicans Candida which was consistent with our study.
Our study showed an increase in the antifungal drug resistance, especially for the azole group of drugs, both in C. albicans and nonalbicans Candida species. The study by Chander et al. [1] and Kothari and Sagar. [15] also showed high resistance to fluconazole. But the study done by Zhang et al. [16] over a period of 10 years in China showed a very low resistance to fluconazole. We observed no resistance to amphotericin B in any of the strains, which is in concordance with the findings of previous studies from India. [13] Our study has a number of limitations. It was a retrospective study conducted at a single institution. More number of studies should be done in a larger population. Antifungal susceptibility test was done by disk diffusion method, but minimum inhibitory concentration should also have been determined. Susceptibility to echinocandins and flucytosine were not tested. Furthermore, no follow-up was done on the patients on the treatment and outcome, which is a major limitation.
CONCLUSION
Candidemia in hospitalized patients is a significant problem worldwide. Nonalbicans Candida species, especially C. tropicalis is the most frequent pathogen isolated in our tertiary care center. Based on the present results, it is evident that routine identification of Candida isolates to the species level, and the detection of resistant strains by antifungal susceptibility test is essential. Furthermore, there is a continued need for surveillance of candidemia to monitor changes in the epidemiological features and antifungal susceptibility and also to develop and evaluate prevention strategies.
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